 BRIDGEWATER, N.J., Dec. 29, 2020 GLOBE NEWSWIRE -- Osmotica Pharmaceuticals plc Nasdaq: OSMT Osmotica or the Company today announced that the U.S. Food and Drug Administration FDA has issued a Complete Response Letter CRL regarding the Companys New Drug Application NDA seeking approval for the investigational agent arbaclofen extended release ER tablets to treat spasticity resulting from multiple sclerosis. 